HROW · Harrow, Inc.
$39.64
-0.40 (-0.99%)
At close · Aug 17
Market Cap
$1.50B
Shares
37.49M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$40.03
Open$39.21
Day$38.87–41.24
52W close$29.03–54.80
Avg vol 30d587K
Short int6.8M · 18.1% float · 11.8d
Short vol70%
Last earningsAug 11, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
−1%
below
RSI (14)
49
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−22%
trailing
YTD return
−18%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $41 › 200d $41 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
18.09% of float · ▼ -0.9% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
222 holders — near 3-yr high, broad support
Squeeze score
83
high risk · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
Gross margin
75%
contracting
EPS growth
+71%
Y/Y
Free cash flow
$43.0M
Balance sheet
$177.1M
net debt
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
full-year 2026
Revenue
Initiated
$350M – $365M
prior FY $272.3M
midpoint +31.3% Y/Y
Adjusted EBITDA
Non-GAAP
Initiated
$80M – $100M
2027
TYRVAYA revenue
at least $30M
Prior guidance
period ended
· from the 8-K filed May 11, 2026
Revenue
· Second Quarter
$71M – $81M
Guided vs delivered
· last 1 settled
Full-year revenue
full-year 2025
guided $270M – $280M
$272.3M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
−1%
Neutral
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $41 › 200d $41 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
18.09% of float · ▼ -0.9% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
222 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $29
Now $40 · 43%
Range high $55
vs 200-day avg -3%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$13,891,000 | Six Months Ended June 30, 2026 | — |
|
|
|||
| IHEEZO First-ever ordering accounts in the quarter | 62 | Q2 2026 | — |
| IHEEZO Reorder rate | 85.5% | Q2 2026 | — |
| IHEEZO Total ordering accounts | 224 | Q2 2026 | — |
| IHEEZO trailing twelve-month reorder rate | 85.5% | Q2 2026 | — |
| IHEEZO Unit demand | 65,477 | Q2 2026 | — |
| TRIESENCE Total ordering accounts | 805 | Q2 2026 | — |
| TRIESENCE Unit demand | 14,529 | Q2 2026 | — |
| VEVYE Branded TRx market share | 14.6% | Q2 2026 | — |
| VEVYE New prescriptions (NRx) sequential growth | 4% | Q2 2026 | — |
| VEVYE Total prescriptions (TRx) sequential growth | 21% | Q2 2026 | — |
| VEVYE Unique prescribers sequential growth | 15% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HROW
this stock
Harrow, Inc.
|
$1.50B | -18.3% | +36.4% | — | 18.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HROW | -1.0% | -14.2% | -22.4% | +3.3% | -18.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.4% | -18.6% | -36.1% | -0.7% | -32.2% |
Key facts
CIK
1360214
CUSIP
415858109
13F (30d)
214 filings
209 filers
Visit website
Investor relations